证券代码：000915 证券简称：华特达因 公告编号：2025-032 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东华特达因健康股份有限公司第十一届董事会于 2025 年 7 月 26 日以电子邮件形式发出召开第四次会议的通知，并于 2025 年 8 月 6 日在公司会议室召开会议。会议应参加董事 8 名，实际参加董事 8 名。会议由公司董事长朱效平先生主持。会议符合有关法律、法规、 规章和《公司章程》的规定。 二、董事会会议审议情况 1.以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2025 年半年度报告》。 《公司 2025 年半年度报告》已经公司第十一届董事会审计委员 会审议通过。审计委员会认为：公司董事会编制的"2025 年半年度 报告"真实、准确、完整地反映了公司的财务状况和经营成果，同意 将报告提交公司董事会审议。 2.以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2025 年中期利润分配预案》。 公司拟定 2025 年中期利润分配预案为：以 2025 年 6 月 30 日 ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=Item%201.%20Important%20Notice%2C%20Table%20of%20Contents%2C%20and%20Definitions) This section provides essential preliminary information including the table of contents and key definitions [Company Profile and Key Financial Indicators](index=6&type=section&id=Item%202.%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section presents the company's fundamental information and a summary of its key financial performance and position [Company Profile](index=6&type=section&id=I.%20Company%20Profile) This section outlines the company's fundamental details, including stock information, legal representation, and contact persons Company Basic Information | Item | Information | | :--- | :--- | | Stock Abbreviation | Huatedain | | Stock Code | 000915 | | Listing Exchange | Shenzhen Stock Exchange | | Legal Representative | Zhu Xiaoping | [Key Accounting Data and Financial Indicators](index=6&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In H1 2025, the company achieved revenue of 1.17 billion yuan, a 1.39% increase, and net profit attributable to shareholders of 337 million yuan, up 1.69%; operating cash flow significantly rose by 61.44% to 675 million yuan due to increased sales receipts, while total assets and net assets attributable to shareholders slightly decreased from year-end H1 2025 Key Financial Data | Indicator | Current Period (Yuan) | Prior Period (Yuan) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (Yuan) | 1,170,478,273.18 | 1,154,413,477.20 | 1.39% | | Net Profit Attributable to Shareholders (Yuan) | 337,467,373.75 | 331,871,287.24 | 1.69% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) (Yuan) | 332,340,551.27 | 318,600,238.57 | 4.31% | | Net Cash Flow from Operating Activities (Yuan) | 674,608,179.59 | 417,869,236.68 | 61.44% | | Basic Earnings Per Share (Yuan/Share) | 1.44 | 1.42 | 1.41% | | Weighted Average Return on Net Assets | 10.96% | 10.81% | Increase 0.15 percentage points | | | **End of Current Period (Yuan)** | **End of Prior Year (Yuan)** | **YoY Change** | | Total Assets (Yuan) | 4,596,433,238.58 | 4,930,936,591.73 | -6.78% | | Net Assets Attributable to Shareholders (Yuan) | 2,780,455,844.63 | 2,911,651,440.88 | -4.51% | [Non-recurring Gains and Losses and Amounts](index=7&type=section&id=VI.%20Non-recurring%20Gains%20and%20Losses%20and%20Amounts) During the reporting period, the company's total non-recurring gains and losses amounted to 5.13 million yuan, primarily comprising government grants and fair value changes from financial assets held by non-financial enterprises Non-recurring Gains and Losses Items | Item | Amount (Yuan) | | :--- | :--- | | Government grants recognized in current profit or loss | 4,015,833.88 | | Gains and losses from financial assets and liabilities held by non-financial enterprises | 8,225,702.67 | | Other non-operating income and expenses | -827,564.67 | | Other gains and losses meeting the definition of non-recurring items | 8,161.73 | | Less: Income tax impact | 1,735,677.91 | | Less: Impact on minority interests (after tax) | 4,559,633.22 | | **Total** | **5,126,822.48** | [Management Discussion and Analysis](index=8&type=section&id=Item%203.%20Management%20Discussion%20and%20Analysis) This section provides an in-depth analysis of the company's operations, financial performance, and future outlook [Company's Main Business](index=8&type=section&id=I.%20Main%20Business%20Activities%20During%20the%20Reporting%20Period) The company primarily engages in R&D, production, and sales of pediatric pharmaceuticals and health products, with core revenue and profit from its subsidiary Dayin Pharmaceutical, which contributed 98.59% of total revenue in H1; despite industry pressures and declining birth rates, the company benefits from national pro-child health policies, maintains a strong market position with its flagship product 'Yikexin,' expands its nutrition product line, and drives growth through integrated online-offline marketing - The company's main business is pediatric pharmaceutical and health products, with core subsidiary Dayin Pharmaceutical contributing **98.59%** of H1 operating revenue, totaling **1.15 billion yuan**[27](index=27&type=chunk) - At the industry level, pharmaceutical manufacturing faces downstream sales pressure, but national policies encouraging childbirth and child health present development opportunities for the pediatric pharmaceutical sector[25](index=25&type=chunk)[26](index=26&type=chunk) - The company has established a comprehensive product matrix covering pharmaceuticals and nutritional health products, with its flagship product 'Yikexin' holding a leading market share, while also expanding into nutritional health products like DHA and probiotics[27](index=27&type=chunk)[28](index=28&type=chunk) - The company employs a core marketing strategy of 'expert authoritative recommendation, convenient channel purchase, and professional category education,' building an integrated online and offline sales network[33](index=33&type=chunk) [Analysis of Core Competencies](index=12&type=section&id=II.%20Analysis%20of%20Core%20Competencies) The company's core competencies are five-fold: professional expertise from long-term dedication to child health; strong R&D capabilities with a national enterprise technology center and pediatric drug research institute; significant brand advantage from its flagship product 'Yikexin'; product advantages of precision, safety, and palatability under a 'tailor-made' philosophy; and enhanced production efficiency through digitalization and intelligence - The company's core competencies include: - **Professional Advantage**: Long-term focus on child health, establishing an industry-leading position - **R&D Advantage**: Possesses national enterprise technology centers and pediatric drug research institutes, undertaking multiple national-level projects and securing **72** national patents - **Brand Advantage**: Flagship product 'Yikexin' has a brand value of **4.98 billion yuan**, with the company's overall brand value reaching **23.13 billion yuan** - **Product Advantage**: 'Tailor-made' philosophy ensures products precisely meet children's needs in formulation, dosage form, and taste - **Production Advantage**: Operates multiple dosage form production lines with a stringent quality management system, enhancing efficiency through digitalization[37](index=37&type=chunk)[38](index=38&type=chunk)[39](index=39&type=chunk)[40](index=40&type=chunk)[41](index=41&type=chunk)[42](index=42&type=chunk) [Analysis of Main Business Operations](index=13&type=section&id=III.%20Analysis%20of%20Main%20Business%20Operations) During the reporting period, the company's operating revenue and cost slightly increased, while administrative expenses and R&D investment decreased year-on-year; net cash flow from operating activities grew strongly by 61.44% due to increased sales collections; the pharmaceutical business, as the core, accounted for 98.59% of revenue with a stable gross margin of 85.97% Key Financial Data Year-on-Year Changes | Item | Current Period (Yuan) | Prior Period (Yuan) | YoY Change | Main Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 1,170,478,273.18 | 1,154,413,477.20 | 1.39% | - | | Administrative Expenses | 32,655,349.50 | 42,245,770.42 | -22.70% | - | | R&D Investment | 37,670,527.52 | 49,054,395.48 | -23.21% | - | | Net Cash Flow from Operating Activities | 674,608,179.59 | 417,869,236.68 | 61.44% | Due to increased cash received from sales of goods and services in the current period | Operating Revenue by Industry Segment | Industry | Operating Revenue (Yuan) | % of Total Revenue | Gross Margin | YoY Change | | :--- | :--- | :--- | :--- | :--- | | Pharmaceutical | 1,153,990,176.91 | 98.59% | 85.97% | 1.57% | | Other | 16,488,096.27 | 1.41% | - | -9.84% | [Analysis of Assets and Liabilities](index=14&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) As of the end of the reporting period, total assets were 4.60 billion yuan, a 6.78% decrease from year-end; asset structure remained stable with cash and equivalents accounting for 45.06% of total assets; no significant changes in liabilities; 24.74 million yuan in cash was frozen due to deposits and legal disputes, restricting its rights Changes in Major Asset Components | Asset Item | Period-end Amount (Yuan) | % of Total Assets | Change from Prior Year-end | | :--- | :--- | :--- | :--- | | Cash and Equivalents | 2,071,365,381.51 | 45.06% | 2.09% | | Fixed Assets | 826,586,254.98 | 17.98% | 0.66% | | Financial Assets Held for Trading | 697,599,794.52 | - | - | - As of the end of the reporting period, **24.74 million yuan** in cash and equivalents was frozen due to guarantee deposits and legal disputes, resulting in restricted asset rights[53](index=53&type=chunk) [Analysis of Major Holding and Participating Companies](index=16&type=section&id=VIII.%20Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) The company's primary source of profit is its controlled subsidiary, Shandong Dayin Marine Biotechnology Co., Ltd.; during the reporting period, Dayin Pharmaceutical achieved operating revenue of 1.14 billion yuan and net profit of 633 million yuan, serving as the core support for the company's performance Shandong Dayin Marine Biotechnology Co., Ltd. Key Financial Data | Indicator | Amount (Yuan) | | :--- | :--- | | Total Assets | 3,069,883,120.55 | | Net Assets | 2,636,850,885.09 | | Operating Revenue | 1,135,917,144.76 | | Operating Profit | 737,506,983.20 | | Net Profit | 633,104,950.93 | [Risks and Countermeasures](index=17&type=section&id=X.%20Risks%20and%20Countermeasures) The company faces two main risks: market challenges from downstream sales pressure and declining birth rates, and potential risks in managing and disposing of non-core businesses and assets (e.g., Huate Zhixin Materials, Wolong School) that may not meet expectations; the company plans to address market challenges by deepening market penetration, diversifying product lines, and strengthening online marketing, while actively promoting compliant handling of non-core assets - **Market Risk**: Downstream sales pressure in the pharmaceutical industry and declining birth rates adversely impact demand for infant and child nutrition and health products[63](index=63&type=chunk) - **Countermeasures**: Enhance the penetration rate of the core product 'Yikexin,' strengthen marketing for key products, and vigorously develop online channels to precisely meet customer needs[63](index=63&type=chunk) - **Management Risk**: The liquidation of non-core business (Huate Zhixin Materials) and resolution of asset occupation issues (Wolong School) may face risks of not progressing as expected[64](index=64&type=chunk) - **Countermeasures**: Continuously focus on the core pediatric pharmaceutical and health business, formulate detailed plans to actively promote the disposal of non-core businesses and assets, and protect company interests[64](index=64&type=chunk) [Corporate Governance, Environment, and Society](index=17&type=section&id=Item%204.%20Corporate%20Governance%2C%20Environment%2C%20and%20Society) This section details the company's governance structure, environmental initiatives, and social responsibility efforts [Profit Distribution Plan](index=18&type=section&id=II.%20Profit%20Distribution%20and%20Capital%20Reserve%20Conversion%20in%20the%20Current%20Period) The Board of Directors approved the H1 2025 profit distribution plan, proposing a cash dividend of 5 yuan (tax inclusive) per 10 shares to all shareholders based on the total share capital as of June 30, 2025, with no bonus shares or capital reserve conversions; this proposal awaits shareholder approval H1 2025 Profit Distribution Proposal | Item | Content | | :--- | :--- | | Dividend per 10 shares (Yuan) (tax inclusive) | 5 | | Bonus shares per 10 shares (shares) | 0 | | Share capital base for distribution proposal (shares) | 234,331,485 | | Cash dividend amount (Yuan) (tax inclusive) | 117,165,742.50 | [Social Responsibility](index=18&type=section&id=V.%20Social%20Responsibility) The company actively fulfills its social responsibilities through its subsidiary Dayin Pharmaceutical, focusing on child health; key initiatives include: disseminating scientific parenting knowledge via multimedia platforms; promoting the improvement of pediatric drug policies and standards; establishing the 'Dayin Love Fund' to aid children in need; and conducting various charitable activities such as donating medicines and supporting rural education, comprehensively safeguarding children's healthy growth - Continuously disseminates popular science content on child nutrition, health, and scientific medication through systematic communication matrices, including social media and self-media, in collaboration with expert organizations[73](index=73&type=chunk) - Actively assumes industry responsibility, leading the establishment of a pediatric drug professional committee to promote the promulgation of relevant policies and standards[74](index=74&type=chunk) - Actively gives back to society through the 'Dayin Love Fund' and various public welfare projects, such as donating pediatric medicines to flood-affected areas in Guizhou and building hope primary schools[75](index=75&type=chunk)[76](index=76&type=chunk) [Significant Matters](index=19&type=section&id=Item%205.%20Significant%20Matters) This section reports on key events and transactions impacting the company during the reporting period [Litigation Matters](index=20&type=section&id=VIII.%20Litigation%20Matters) The company had no significant litigation or arbitration matters during the reporting period; there was one other lawsuit involving an engineering payment dispute with former subsidiary Shandong Huate Smart Technology Co., Ltd., with an amount of 3.79 million yuan, for which Huate Smart is responsible for the related payables - The company had no significant litigation or arbitration matters during the reporting period[84](index=84&type=chunk) [Significant Related Party Transactions](index=20&type=section&id=XI.%20Significant%20Related%20Party%20Transactions) During the reporting period, the company did not engage in significant related party transactions related to daily operations, nor did it undertake other major related party transactions such as asset or equity acquisitions or disposals - The company did not engage in significant related party transactions related to daily operations during the reporting period[86](index=86&type=chunk) [Share Changes and Shareholder Information](index=22&type=section&id=Item%206.%20Share%20Changes%20and%20Shareholder%20Information) This section details changes in share capital and provides an overview of the company's shareholder structure [Shareholder Numbers and Shareholding](index=23&type=section&id=III.%20Shareholder%20Numbers%20and%20Shareholding) As of the end of the reporting period, the company had 25,635 common shareholders; the controlling shareholder is Shandong Huate Holding Group Co., Ltd., with a 22.00% stake; among the top ten shareholders, Guo Weisong is the second largest, holding 8.78% - The total number of common shareholders at the end of the reporting period was **25,635**[106](index=106&type=chunk) Top Five Shareholders' Shareholding | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | :--- | | Shandong Huate Holding Group Co., Ltd. | State-owned Legal Person | 22.00% | 51,544,340 | | Guo Weisong | Domestic Natural Person | 8.78% | 20,581,124 | | Yin Juntao | Domestic Natural Person | 3.52% | 8,246,393 | | Hong Kong Securities Clearing Company Limited | Overseas Legal Person | 3.15% | 7,389,501 | | Huitianfu Fund Management Co., Ltd. - Social Security Fund 17022 Portfolio | Other | 1.94% | 4,542,984 | [Bond-Related Information](index=25&type=section&id=Item%207.%20Bond-Related%20Information) This section provides details on any bond-related activities or outstanding bonds of the company [Bond-Related Information](index=25&type=section&id=Bond%20Related%20Information) The company had no bond-related matters during the reporting period - The company had no bond-related matters in the current reporting period[113](index=113&type=chunk) [Financial Report](index=25&type=section&id=Item%208.%20Financial%20Report) This section presents the company's comprehensive financial statements and notes, detailing its financial position and performance [Financial Statements](index=25&type=section&id=II.%20Financial%20Statements) This section includes the company's unaudited H1 2025 financial statements, comprising consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity - The company's half-year financial report is unaudited[114](index=114&type=chunk) [Significant Accounting Policies and Estimates](index=42&type=section&id=V.%20Significant%20Accounting%20Policies%20and%20Estimates) This section elaborates on the basis of preparation, enterprise accounting standards, and significant accounting policies and estimates followed by the company in preparing its financial statements, covering key areas such as revenue recognition, financial instruments, long-term equity investments, R&D expenditures, and government grants - Financial statements are prepared on a going concern basis, in accordance with enterprise accounting standards[146](index=146&type=chunk)[147](index=147&type=chunk) - Revenue recognition policy: Revenue is recognized when the customer obtains control of the related goods or services, primarily for pharmaceutical product sales, recognized upon customer receipt[203](index=203&type=chunk)[204](index=204&type=chunk) - R&D expenditure policy: Internal R&D projects are divided into research and development phases; research phase expenditures are expensed, while development phase expenditures are capitalized upon meeting specific conditions (e.g., technical and economic feasibility)[191](index=191&type=chunk) [Notes to Consolidated Financial Statement Items](index=57&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This section provides detailed notes and explanations for each major item in the consolidated financial statements, including the composition, changes, and specific circumstances of accounts such as cash and equivalents, accounts receivable, inventories, fixed assets, intangible assets, goodwill, accounts payable, revenue and costs, and various expenses

证券代码：000915 证券简称：华特达因 公告编号：2025-033 山东华特达因健康股份有限公司 关于公司2025年中期利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、审议程序 （一）董事会审议情况 含本次拟实施的 2025 年中期利润分配，公司本年度累计现金分 红总额为 117,165,742.50 元，占半年度公司合并报表归属于上市公司 股东净利润的比例为 34.72%。 本预案将在股东会审议通过之日起两个月内实施完毕。若在实施 前公司总股本因股权激励行权、可转债转股、股份回购等原因而发生 变化的，公司将按照"现金分红分配比例固定不变"的原则对现金分 红总额进行调整。 三、现金分红方案合理性说明 2025 年 8 月 6 日，山东华特达因健康股份有限公司（以下简称 "公司"）第十一届董事会第四次会议审议通过了《公司 2025 年中 期利润分配预案》，本事项尚需提交公司 2025 年第一次临时股东会 审议。 二、2025 年中期利润分配预案的基本情况 公司 2025 年 1-6 月合并实现营业收入 1,170,478,273.18 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、合同签署概况 三、合同主要内容 1. 授权范围：诺贝仁授予达因康健褪黑素颗粒产品在中国大陆地区（不含港澳台）的独家经销权，包括 产品的进口、市场推广及销售。 近日，山东华特达因健康股份有限公司（以下简称公司）的子公司北京达因康健医药有限责任公司（以 下简称达因康健）与日本诺贝仁制药株式会社（Nobelpharma Co.,Ltd）（以下简称"诺贝仁"）就褪黑素 颗粒（商品名：曼乐静?）在中国大陆地区的独家总经销事宜达成一致，并签署了《褪黑素颗粒总经销 协议》。根据协议约定，达因康健将成为诺贝仁旗下褪黑素颗粒产品（曼乐静?）在中国大陆地区（不 含港澳台）的独家总经销商，全面负责该产品的进口、市场推广及销售。 1. 该产品2025年7月已在中国获批上市，商品名为"曼乐静?"； 2. 该产品适应症为用于改善6-15岁神经发育障碍儿童的入睡困难，填补了国内该领域的治疗空白，满足 了临床急需。 二、合作方基本情况 - 公司名称：日本诺贝仁制药株式会社（Nobelphar ...

Group 1 - The Ministry of Finance and the State Taxation Administration announced the resumption of VAT on interest income from newly issued government bonds, local government bonds, and financial bonds starting from August 8 [1] - The Hong Kong High Court ruled that Zong Fuli cannot withdraw or transfer any assets from the bank account of Jianhao Venture Capital Limited until the litigation results are finalized [1] - The U.S. non-farm payrolls increased by only 73,000 in July, the lowest in nine months, significantly below the expected 110,000, indicating a rapid slowdown in the labor market [1] Group 2 - The central bank emphasized the implementation of a moderately loose monetary policy and enhancing the effectiveness of monetary policy measures [2] - The National Development and Reform Commission plans to accelerate the establishment of new policy financial tools to support private enterprises in major national projects [2] - The Supreme Court issued judicial interpretations on labor disputes, clarifying that agreements not to participate in social insurance are invalid [2] Group 3 - The Ministry of Finance reported six typical cases of local government hidden debt, with Xiamen, Chengdu, and Wuhan East Lake New Technology Development Zone adding hidden debts of 68.396 billion, 61.408 billion, and 10.385 billion respectively [3] Group 4 - The A-share market experienced a decline, with the Shanghai Composite Index falling by 0.37% to 3559.95 points, and the total trading volume for the day was 1.62 trillion [4] - The Hong Kong Hang Seng Index closed down 1.07% at 24507.81 points, marking four consecutive days of decline [5] Group 5 - The Hong Kong Stock Exchange published a consultation summary on optimizing IPO pricing and public market regulations, allowing a reduction in the minimum allocation ratio for IPO book-building from 50% to 40% [5] - The Shanghai Stock Exchange clarified that pre-application consultation is not a mandatory procedure for project acceptance [5] Group 6 - In the electric vehicle sector, July delivery figures showed significant growth for several companies, with Leap Motor surpassing 50,000 deliveries for the first time [9] - The Ministry of Industry and Information Technology issued a digital transformation implementation plan for the machinery industry, aiming for 50% of enterprises to reach a maturity level of two or above by 2027 [10] Group 7 - The State Administration of Foreign Exchange outlined key tasks for foreign exchange management, emphasizing the need for macro-prudential management of cross-border capital flows [21] - The onshore RMB closed at 7.2106 against the USD, down 176 basis points from the previous trading day [21]

面对每天上千份上市公司公告该看哪些？重大事项公告动辄几十页几百页重点是啥？公告里 一堆专业术语不知道算利好还是利空？请看智通财经公司新闻部《速读公告》栏目，我们派 驻全国的记者们将于公告当晚为您带来准确、快速、专业的解读。 智通财经8月1日讯（记者 何凡）上月，日本诺贝仁制药株式会社（Nobelpharma Co.,Ltd）（以下简 称"诺贝仁"）旗下褪黑素颗粒产品（曼乐静®）在国内获批上市，成为国内首个获批用于改善6-15岁神 经发育障碍儿童的入睡困难的褪黑素制剂。今日华特达因（000915.SZ）官宣获得该药物在中国大陆地 区的独家总经销。资料显示，长春高新（000661.SZ）、亿帆医药（002019.SZ）等药企已在该适应症领 域有所布局。 据悉，曼乐静已于今年7月在国内获批上市，该产品适应症为用于改善6-15岁神经发育障碍儿童的入睡 困难，是我国首个获批用于上述适应症的褪黑素制剂，同时也是褪黑素类物质在国内首次以药品身份获 得上市许可。 合作方诺贝仁成立于2003年，专注于罕见病药品研发与生产。已在中国成功获批三款产品，其褪黑素颗 粒产品（曼乐静®）于2020年在日本上市销售。其余两款药品分别是用于 ...

每经AI快讯，有投资者在投资者互动平台提问：近期二级市场行情火爆，贵公司股价却萎靡不振，坊 间传闻贵公司半年度业绩不佳，一些消息灵通的大户提前撤退，将筹码抛售给不明真相的散户。请问是 否属实？ 华特达因（000915.SZ）8月1日在投资者互动平台表示，公司2025年半年度报告定于2025年8月8日披 露，业绩情况请您以公司披露的《2025年半年度报告》为准。 （文章来源：每日经济新闻） ...

格隆汇8月1日丨华特达因(000915.SZ)公告称，子公司北京达因康健与日本诺贝仁制药株式会社就褪黑 素颗粒(曼乐静®)在中国大陆地区的独家总经销事宜达成一致，并签署《褪黑素颗粒总经销协议》。达 因康健将成为该产品在中国大陆地区（不含港澳台）的独家总经销商。该产品于2025年7月在中国获批 上市，商品名为"曼乐静®"。该产品是我国首个获批用于治疗6-15岁神经发育障碍儿童入睡困难的褪黑 素制剂，同时也是褪黑素类物质在国内首次以药品身份获得上市许可。 ...

证券代码：000915 证券简称：华特达因 公告编号 2025-030 山东华特达因健康股份有限公司 关于子公司签署褪黑素颗粒（曼乐静®）总经销合同的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、合同签署概况 近日，山东华特达因健康股份有限公司（以下简称公司）的子公司北京达因 康健医药有限责任公司（以下简称达因康健）与日本诺贝仁制药株式会社 （Nobelpharma Co.,Ltd）（以下简称"诺贝仁"）就褪黑素颗粒（商品名：曼乐静 ®）在中国大陆地区的独家总经销事宜达成一致，并签署了《褪黑素颗粒总经销 协议》。根据协议约定，达因康健将成为诺贝仁旗下褪黑素颗粒产品（曼乐静®） 在中国大陆地区（不含港澳台）的独家总经销商，全面负责该产品的进口、市场 推广及销售。 1. 该产品 2025 年 7 月已在中国获批上市，商品名为"曼乐静®"； 三、合同主要内容 1. 授权范围：诺贝仁授予达因康健褪黑素颗粒产品在中国大陆地区（不含港 澳台）的独家经销权，包括产品的进口、市场推广及销售。 2. 合作期限：协议初始期限为 10 年，届满后经双方协商可续签。 3. ...

华特达因公告，子公司北京达因康健医药有限责任公司与日本诺贝仁制药株式会社签署褪黑素颗粒总经 销协议。根据协议，达因康健成为诺贝仁旗下褪黑素颗粒产品（曼乐静®）在中国大陆地区（不含港澳 台）的独家总经销商，负责进口、市场推广及销售。该产品已在中国获批上市，用于改善6-15岁神经发 育障碍儿童的入睡困难。合作期限为10年，届满后可续签。 ...